Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.37 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16652047 | 1.00 | ATR (0.42) | ATRNPC1RAB9ACYP17A1LNPEP | |
| SCHEMBL16418530 | 0.83 | ATR (0.41) | ATRCYP17A1PSMB8NAMPTMETAP1 | |
| SCHEMBL30551549 | 0.83 | ATR (0.41) | ATRCYP17A1PSMB8NAMPTMETAP1 | |
| SCHEMBL5053503 | 0.77 | NOS3 (0.46) | NPC1RAB9ALNPEPNOS3NOS1 | |
| SCHEMBL21879335 | 0.76 | KCNQ2 (0.43) | NPC1RAB9ALNPEPNOS3NOS1 | |
| SCHEMBL15264820 | 0.76 | ATR (0.48) | ATRNPC1RAB9ACYP17A1PSMB8 | |
| SCHEMBL25144741 | 0.75 | ALDH1A1 (0.55) | — | |
| SCHEMBL28797276 | 0.74 | NLRP3 (0.56) | NLRP3 | |
| SCHEMBL21401838 | 0.73 | PTPN1 (0.40) | NPC1RAB9ALNPEPNOS3NOS1 | |
| SCHEMBL22249470 | 0.73 | ATR (0.51) | ATRCYP17A1NAMPTMETAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| EP-4565574-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20250049780-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. | 2025-02-13 | — | — | US | disclosed |
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-12070455-B2 | Thienopyrrole compounds | GILEAD SCIENCES, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
| EP-4398989-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-07-17 | — | — | EP | disclosed |
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-04-11 | — | — | US | disclosed |
| WO-2024031089-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| US-20230270734-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. | 2023-08-31 | — | — | US | disclosed |
| WO-2023039464-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | ATR 3672/4885NPC1 848/4885RAB9A 2168/4885 |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | ACE2, TMPRSS2, ACE | ATR 3672/4885NPC1 848/4885RAB9A 2168/4885 |
| US-20230270734-A1 | THIENOPYRROLE COMPOUNDS | SSB, TPMT, LCP2 | ATR 1284/4885NPC1 3660/4885RAB9A 2741/4885 |
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | ATR 3672/4885NPC1 848/4885RAB9A 2168/4885 |
| US-20250049780-A1 | THIENOPYRROLE COMPOUNDS | SSB, TPMT, LCP2 | ATR 1284/4885NPC1 3660/4885RAB9A 2741/4885 |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | ACE2, TMPRSS2, ACE | ATR 3672/4885NPC1 848/4885RAB9A 2168/4885 |
| US-12070455-B2 | Thienopyrrole compounds | SSB, TPMT, LCP2 | ATR 1284/4885NPC1 3660/4885RAB9A 2741/4885 |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | ATR 3672/4885NPC1 848/4885RAB9A 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.